IC50, EC50 i Ki dla 5-HT2C: Antydepresanty

Content may be unverified or unsafe. Report
ChatGPT
Citations

Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor - PubMed

https://pubmed.ncbi.nlm.nih.gov/8876023/

fluoxetine | Ligand Activity Charts | IUPHAR/BPS Guide to PHARMACOLOGY

https://www.guidetopharmacology.org/GRAC/LigandActivityRangeVisForward?ligandId=203

Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor - PubMed

https://pubmed.ncbi.nlm.nih.gov/8876023/

Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor - PubMed

https://pubmed.ncbi.nlm.nih.gov/8876023/

The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways - PubMed

https://pubmed.ncbi.nlm.nih.gov/12750432/

The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways - PubMed

https://pubmed.ncbi.nlm.nih.gov/12750432/

The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways - PubMed

https://pubmed.ncbi.nlm.nih.gov/12750432/

Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties - PubMed

https://pubmed.ncbi.nlm.nih.gov/24724693/

mirtazapine | Ligand Activity Charts | IUPHAR/BPS Guide to PHARMACOLOGY

https://www.guidetopharmacology.org/GRAC/LigandActivityRangeVisForward?ligandId=7241

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram - PubMed

https://pubmed.ncbi.nlm.nih.gov/10762339/

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram - PubMed

https://pubmed.ncbi.nlm.nih.gov/10762339/

SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in rats | BMC Neuroscience | Full Text

https://bmcneurosci.biomedcentral.com/articles/10.1186/1471-2202-13-65

Serotonin 5-HT2C receptor stimulates cyclic GMP formation in choroid plexus - PubMed

https://pubmed.ncbi.nlm.nih.gov/7798914/

Serotonin 5-HT2C receptor-mediated phosphoinositide hydrolysis in rat choroid plexus after fluoxetine and citalopram treatments - PubMed

https://pubmed.ncbi.nlm.nih.gov/15749456/

Trazodone is a potent agonist at 5-HT2C receptors mediating inhibition of the N-methyl-D-aspartate/nitric oxide/cyclic GMP pathway in rat cerebellum - PubMed

https://pubmed.ncbi.nlm.nih.gov/9618398/

Trazodone is a potent agonist at 5-HT2C receptors mediating inhibition of the N-methyl-D-aspartate/nitric oxide/cyclic GMP pathway in rat cerebellum - PubMed

https://pubmed.ncbi.nlm.nih.gov/9618398/

mirtazapine | Ligand Activity Charts | IUPHAR/BPS Guide to PHARMACOLOGY

https://www.guidetopharmacology.org/GRAC/LigandActivityRangeVisForward?ligandId=7241

The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways - PubMed

https://pubmed.ncbi.nlm.nih.gov/12750432/

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram - PubMed

https://pubmed.ncbi.nlm.nih.gov/10762339/